Quercetin is a flavonoid — a polyphenol compound found widely in plant foods including onions, apples, berries, broccoli, capers, and green tea. It is one of the most studied flavonoids in biochemistry and has an extensive in vitro evidence base for antioxidant, anti-inflammatory, antihistamine, antiviral, and cardioprotective properties. In laboratory conditions, quercetin inhibits histamine release from mast cells, scavenges reactive oxygen species, inhibits NF-κB (a major inflammatory signalling pathway), and has shown antiviral activity against several respiratory viruses.
The problem is getting it into the body. Quercetin is relatively insoluble in water and has poor intestinal absorption from standard aglycone (free quercetin) supplements. Much of a typical quercetin dose is not absorbed in the small intestine and instead passes to the colon, where gut bacteria metabolise it — producing various metabolites with potentially different biological activity but lower concentrations of the parent compound in plasma.
Studies measuring plasma quercetin concentrations after standard oral supplementation consistently show limited absorption. A pharmacokinetic study by Hollman et al. (1997) compared quercetin absorption from onions (where quercetin occurs as glycosides — quercetin bound to sugars) versus pure quercetin aglycone. Onion quercetin glycosides showed 52% absorption; pure aglycone showed only 24%. This counterintuitive finding suggests that the sugar moieties in food-based quercetin actually facilitate intestinal transport via sodium-dependent glucose transporters.
In practical terms, standard quercetin aglycone powder supplements — the most commonly sold form — may achieve only 20–30% absorption, and much of that may be as metabolites rather than intact quercetin. For the anti-inflammatory, antihistamine, and antiviral mechanisms attributed to quercetin, the relevant question is what concentration of active compound reaches target tissues — and standard supplements may deliver substantially less than the marketed dose implies.
As with curcumin phytosome (Meriva®), quercetin phytosome binds quercetin to phosphatidylcholine to create a lipid-compatible complex. Quercefit® is the most studied proprietary quercetin phytosome, developed by Indena SpA. A 2019 pharmacokinetic study by Riva et al. published in Minerva Gastroenterologica e Dietologica compared Quercefit® to standard quercetin at the same dose. Results showed that Quercefit® achieved plasma quercetin AUC (area under curve — a measure of total systemic exposure) approximately 20 times higher than standard quercetin. This is a substantial bioavailability improvement, though the study was manufacturer-funded and needs independent replication for full confidence.
Liposomal encapsulation of quercetin follows the same principle as liposomal vitamin C — phospholipid vesicles theoretically improve gut absorption by protecting the molecule from intestinal degradation. Human pharmacokinetic data for liposomal quercetin specifically is more limited than for the phytosome form, but early data is promising.
The Hollman data suggests that food-form quercetin glycosides absorb better than aglycone. Isoquercitrin (quercetin-3-glucoside) and rutin are common food-form quercetin glycosides that appear in some supplement formulations and absorb more reliably than pure aglycone. Enzymatically modified isoquercitrin (EMIQ) — where the sugar chain is modified to improve solubility — has shown particularly good absorption in pharmacokinetic studies.
| Form | Bioavailability vs Standard | Evidence Source |
|---|---|---|
| Standard quercetin aglycone | Baseline — low (~20–30%) | Hollman et al. 1997; multiple pharmacokinetic studies |
| Quercetin from onions (glycosides) | ~2x standard aglycone | Hollman et al. 1997 |
| Quercefit® phytosome | ~20x standard aglycone | Riva et al. 2019 (manufacturer-funded) |
| EMIQ (enzymatic isoquercitrin) | Significantly improved | Multiple Japanese pharmacokinetic studies |
| Quercetin + piperine | Modest improvement | Piperine inhibits quercetin glucuronidation; variable data |
Interest in quercetin surged during the COVID-19 pandemic based on the hypothesis that quercetin acts as a zinc ionophore — a molecule that facilitates the transport of zinc ions across cell membranes. Zinc has antiviral properties, but zinc ions do not readily cross lipid cell membranes unaided. Ionophores carry them across. If quercetin acts as a zinc ionophore (as suggested by laboratory studies including Dabbagh-Bazarbachi et al. 2014 in JACS), then combining quercetin with zinc might enhance intracellular zinc delivery and thereby amplify antiviral effects.
The evidence for this hypothesis in humans is mechanistically plausible but not yet confirmed in clinical RCTs for respiratory viral infections. The laboratory evidence for quercetin's ionophore activity is credible; the clinical translation to meaningful antiviral benefit in humans has not been demonstrated in adequately powered controlled trials. This does not make the combination dangerous — zinc and quercetin are both safe supplements — but the "quercetin + zinc for viruses" claim currently exceeds the clinical evidence.
For general anti-inflammatory and antioxidant support, standard quercetin aglycone at 500–1,000 mg/day provides some systemic quercetin exposure, even if absorption is limited. For maximum effect, quercetin phytosome (Quercefit®) at 250–500 mg/day is likely to deliver significantly higher plasma levels at lower stated doses. Take with a fatty meal to enhance absorption of all forms.
Quercetin is often combined with vitamin C (which may recycle quercetin) and bromelain (which may enhance intestinal permeability). The clinical evidence for these combinations is limited but the safety profile is acceptable.
Quercetin has a good safety profile across published human studies. Typical side effects at high doses include mild headache and tingling in the extremities. Long-term high-dose safety data (above 1 g/day for years) is limited.
Quercetin inhibits CYP3A4 and some P-glycoprotein drug transporters, which can increase blood levels of certain medications including cyclosporine, tacrolimus, and some statins. This is clinically relevant for transplant patients and those on narrow therapeutic-index drugs. Quercetin may also inhibit thyroid peroxidase at very high doses — a theoretical concern for people with thyroid conditions.
Quercetin has mild antiplatelet properties — combine with anticoagulants only after discussing with GP.
Quercetin's in vitro properties are impressive and its dietary role in human health is well-documented. The critical limitation for supplement use is poor bioavailability from standard aglycone forms. The phytosome technology (Quercefit®) offers a genuine, if manufacturer-funded, bioavailability improvement. The zinc ionophore synergy is mechanistically interesting but clinically unproven in humans. For people seeking quercetin's antihistamine or anti-inflammatory properties, choosing a well-formulated enhanced-bioavailability product makes the most biological sense.